Tocilizumab (Actemra) for Rheumatoid Arthritis
The FDA has approved tocilizumab (Actemra – Genentech; RoActemra in Europe) for intravenous
(IV) treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an
inadequate response to tumor necrosis factor (TNF) inhibitors....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Tocilizumab (Actemra) for Rheumatoid Arthritis
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1340
Article Code: 1340c
Date: June 14, 2010
Volume: 52
Pages: 47-48
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1340
Article Code: 1340c
Date: June 14, 2010
Volume: 52
Pages: 47-48
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)
